These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 34711976)

  • 21. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
    Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
    Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial.
    Selvaraj S; Patel S; Sauer AJ; McGarrah RW; Jones P; Kwee LC; Windsor SL; Ilkayeva O; Muehlbauer MJ; Newgard CB; Borlaug BA; Kitzman DW; Shah SJ; Shah SH; Kosiborod MN;
    JACC Heart Fail; 2024 Jun; 12(6):999-1011. PubMed ID: 38639697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Claggett B; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Jhund PS; Belohlavek J; Chiang CE; Borleffs CJW; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer-Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Saraiva JFK; Tereshchenko SN; Thierer J; Vaduganathan M; Vardeny O; Verma S; Pham VN; Wilderäng U; Zaozerska N; Bachus E; Lindholm D; Petersson M; Langkilde AM;
    N Engl J Med; 2022 Sep; 387(12):1089-1098. PubMed ID: 36027570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF.
    Lewis GD; Gosch K; Cohen LP; Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Kosiborod MN; Sauer AJ
    Circ Heart Fail; 2023 Nov; 16(11):e010633. PubMed ID: 37869881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
    Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
    Schou M; Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Patel S; Chinnakondepalli KM; Harring S; Abildstrøm SZ; Liisberg K; Kosiborod MN;
    J Am Coll Cardiol; 2024 Jul; 84(3):247-257. PubMed ID: 38913004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
    Yang M; Kondo T; Talebi A; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2024 Jul; 26(7):1524-1538. PubMed ID: 38700986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
    Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS
    JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
    Coats AJS; Butler J; Tsutsui H; Doehner W; Filippatos G; Ferreira JP; Böhm M; Chopra VK; Verma S; Nordaby M; Iwata T; Nitta D; Ponikowski P; Zannad F; Packer M; Anker SD
    J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):412-424. PubMed ID: 38158636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
    Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
    JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
    Abraham WT; Lindenfeld J; Ponikowski P; Agostoni P; Butler J; Desai AS; Filippatos G; Gniot J; Fu M; Gullestad L; Howlett JG; Nicholls SJ; Redon J; Schenkenberger I; Silva-Cardoso J; Störk S; Krzysztof Wranicz J; Savarese G; Brueckmann M; Jamal W; Nordaby M; Peil B; Ritter I; Ustyugova A; Zeller C; Salsali A; Anker SD
    Eur Heart J; 2021 Feb; 42(6):700-710. PubMed ID: 33351892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.